NYSEAMERICAN:MTNB

Matinas Biopharma Q2 2026 Earnings Results & Report

Matinas Biopharma logo
$0.91 +0.05 (+6.35%)
As of 04:10 PM Eastern

Matinas Biopharma reported Q2 2026 earnings on August 13, 2026. The company reported EPS of -$3.15.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Matinas Biopharma EPS Results

Actual EPS
-$3.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

Matinas Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Matinas Biopharma Q2 2026 Earnings FAQ

Matinas Biopharma (NYSEAMERICAN:MTNB) reported earnings of -$3.15 per share for Q2 2026. The report was announced on Thursday, August 13, 2026.

Matinas Biopharma Earnings Headlines

The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSEAMERICAN:MTNB) is a biopharmaceutical company focused on developing medicines using its lipid nanocrystal (LNC) delivery technology. The platform is designed to help deliver drugs that can be difficult to administer or absorb, including through oral formulations.

The company’s development programs have included MAT2203, an oral formulation of amphotericin B studied for serious fungal infections, and MAT2501, an oral formulation of amikacin investigated for difficult-to-treat bacterial infections. These programs have been intended to offer alternatives to conventional routes of administration.

Matinas has also explored its LNC platform for delivering other types of therapeutics. Its work has primarily centered on drug development rather than selling a broad range of commercial medicines.

View Matinas Biopharma Profile